Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.67
ALKS's Cash-to-Debt is ranked lower than
75% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. ALKS: 1.67 )
Ranked among companies with meaningful Cash-to-Debt only.
ALKS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 1.68 Max: No Debt
Current: 1.67
0.04
No Debt
Equity-to-Asset 0.65
ALKS's Equity-to-Asset is ranked lower than
53% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALKS: 0.65 )
Ranked among companies with meaningful Equity-to-Asset only.
ALKS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.67 Max: 0.97
Current: 0.65
-0.15
0.97
Debt-to-Equity 0.24
ALKS's Debt-to-Equity is ranked higher than
54% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. ALKS: 0.24 )
Ranked among companies with meaningful Debt-to-Equity only.
ALKS' s Debt-to-Equity Range Over the Past 10 Years
Min: -34.56  Med: 0.27 Max: 67.51
Current: 0.24
-34.56
67.51
Debt-to-EBITDA 76.95
ALKS's Debt-to-EBITDA is ranked lower than
100% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. ALKS: 76.95 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ALKS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.58  Med: -2.7 Max: 76.95
Current: 76.95
-11.58
76.95
Piotroski F-Score: 6
Altman Z-Score: 4.91
Beneish M-Score: -3.02
WACC vs ROIC
13.13%
-11.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -8.85
ALKS's Operating Margin % is ranked higher than
67% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. ALKS: -8.85 )
Ranked among companies with meaningful Operating Margin % only.
ALKS' s Operating Margin % Range Over the Past 10 Years
Min: -35.7  Med: -15.23 Max: 41.29
Current: -8.85
-35.7
41.29
Net Margin % -13.23
ALKS's Net Margin % is ranked higher than
67% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. ALKS: -13.23 )
Ranked among companies with meaningful Net Margin % only.
ALKS' s Net Margin % Range Over the Past 10 Years
Min: -36.15  Med: -19.86 Max: 69.37
Current: -13.23
-36.15
69.37
ROE % -11.90
ALKS's ROE % is ranked higher than
70% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. ALKS: -11.90 )
Ranked among companies with meaningful ROE % only.
ALKS' s ROE % Range Over the Past 10 Years
Min: -18.25  Med: -10.34 Max: 65.64
Current: -11.9
-18.25
65.64
ROA % -7.92
ALKS's ROA % is ranked higher than
72% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ALKS: -7.92 )
Ranked among companies with meaningful ROA % only.
ALKS' s ROA % Range Over the Past 10 Years
Min: -12.04  Med: -8.14 Max: 27.26
Current: -7.92
-12.04
27.26
ROC (Joel Greenblatt) % -26.44
ALKS's ROC (Joel Greenblatt) % is ranked higher than
72% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. ALKS: -26.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALKS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -64.93  Med: -37.45 Max: 116.34
Current: -26.44
-64.93
116.34
3-Year Revenue Growth Rate 11.40
ALKS's 3-Year Revenue Growth Rate is ranked higher than
67% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALKS: 11.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALKS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -20.2  Med: 11.2 Max: 69.6
Current: 11.4
-20.2
69.6
3-Year EPS without NRI Growth Rate -69.90
ALKS's 3-Year EPS without NRI Growth Rate is ranked lower than
93% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. ALKS: -69.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALKS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -28.2 Max: 224
Current: -69.9
0
224
GuruFocus has detected 2 Warning Signs with Alkermes PLC ALKS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALKS's 30-Y Financials

Financials (Next Earnings Date: 2019-02-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ALKS Guru Trades in

Q1 2018

ALKS Guru Trades in Q1 2018

Steven Cohen 12,900 sh (New)
Jim Simons 114,786 sh (New)
PRIMECAP Management 23,292,333 sh (+6.49%)
Paul Tudor Jones 15,666 sh (+23.28%)
Murray Stahl 22,000 sh (unchged)
Jeff Auxier 26,651 sh (unchged)
Vanguard Health Care Fund 8,814,376 sh (-2.81%)
Ken Fisher 91,627 sh (-16.39%)
Pioneer Investments 147,053 sh (-42.57%)
» More
Q2 2018

ALKS Guru Trades in Q2 2018

Vanguard Health Care Fund 8,990,310 sh (+2.00%)
PRIMECAP Management 23,336,493 sh (+0.19%)
Jeff Auxier 26,651 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Ken Fisher 82,397 sh (-10.07%)
Murray Stahl 21,000 sh (-4.55%)
Pioneer Investments 78,147 sh (-46.86%)
» More
Q3 2018

ALKS Guru Trades in Q3 2018

Jeff Auxier 27,651 sh (+3.75%)
Vanguard Health Care Fund 8,990,310 sh (unchged)
Murray Stahl 21,000 sh (unchged)
Ken Fisher 62,421 sh (-24.24%)
PRIMECAP Management 23,273,058 sh (-0.27%)
Pioneer Investments 53,121 sh (-32.02%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SAGE, NAS:NBIX, NAS:EXEL, NAS:AVXS, BOM:532523, HKSE:01548, NAS:SGEN, NAS:TECH, OSTO:SOBI, NAS:IONS, HKSE:01530, XKRX:215600, SZSE:000661, NAS:BLUE, NAS:SRPT, XKRX:128940, NAS:AGIO, TSE:4587, SZSE:300347, NAS:UTHR » details
Traded in other countries:8AK.Germany,
Headquarter Location:Ireland
Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Top Ranked Articles about Alkermes PLC

Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program
ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors with $100K in Losses of Important Deadline – ALKS
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm
February 25th Alkermes Shareholder Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against Alkermes plc – ALKS
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc – ALKS
SHAREHOLDER ALERT: Berger Montague Announces Investigation of Alkermes, plc (NASDAQ: ALKS) (CUSIP: G01767105)
Hagens Berman Notifies Alkermes Public Limited Company (NASDAQ: ALKS) Investors of Securities Fraud Class Action and February 25, 2019 Lead Plaintiff Deadline
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Ratios

vs
industry
vs
history
Forward PE Ratio 57.47
ALKS's Forward PE Ratio is ranked lower than
97% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. ALKS: 57.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 4.54
ALKS's PB Ratio is ranked lower than
63% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ALKS: 4.54 )
Ranked among companies with meaningful PB Ratio only.
ALKS' s PB Ratio Range Over the Past 10 Years
Min: 1.66  Med: 4.32 Max: 9.1
Current: 4.54
1.66
9.1
PS Ratio 4.93
ALKS's PS Ratio is ranked higher than
65% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALKS: 4.93 )
Ranked among companies with meaningful PS Ratio only.
ALKS' s PS Ratio Range Over the Past 10 Years
Min: 2.19  Med: 7.41 Max: 18.85
Current: 4.93
2.19
18.85
Price-to-Free-Cash-Flow 1017.60
ALKS's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. ALKS: 1017.60 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALKS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.29  Med: 43.29 Max: 1524.32
Current: 1017.6
10.29
1524.32
Price-to-Operating-Cash-Flow 69.66
ALKS's Price-to-Operating-Cash-Flow is ranked lower than
88% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. ALKS: 69.66 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALKS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.76  Med: 66.28 Max: 1531.25
Current: 69.66
8.76
1531.25
EV-to-EBIT -50.63
ALKS's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ALKS: -50.63 )
Ranked among companies with meaningful EV-to-EBIT only.
ALKS' s EV-to-EBIT Range Over the Past 10 Years
Min: -17501.7  Med: -30.15 Max: 436.6
Current: -50.63
-17501.7
436.6
EV-to-EBITDA 1383.19
ALKS's EV-to-EBITDA is ranked lower than
100% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. ALKS: 1383.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALKS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1362.6  Med: 4.5 Max: 32983.8
Current: 1383.19
-1362.6
32983.8
EV-to-Revenue 4.76
ALKS's EV-to-Revenue is ranked higher than
67% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. ALKS: 4.76 )
Ranked among companies with meaningful EV-to-Revenue only.
ALKS' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 7.5 Max: 18.7
Current: 4.76
1.4
18.7
Current Ratio 2.85
ALKS's Current Ratio is ranked lower than
64% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ALKS: 2.85 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 5.88 Max: 35.69
Current: 2.85
2.01
35.69
Quick Ratio 2.56
ALKS's Quick Ratio is ranked lower than
65% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. ALKS: 2.56 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.64 Max: 35.69
Current: 2.56
1.95
35.69
Days Inventory 54.54
ALKS's Days Inventory is ranked higher than
75% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. ALKS: 54.54 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s Days Inventory Range Over the Past 10 Years
Min: 33.89  Med: 49.55 Max: 166.33
Current: 54.54
33.89
166.33
Days Sales Outstanding 86.90
ALKS's Days Sales Outstanding is ranked lower than
70% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. ALKS: 86.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.64  Med: 83.75 Max: 94.38
Current: 86.9
71.64
94.38
Days Payable 27.44
ALKS's Days Payable is ranked lower than
68% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. ALKS: 27.44 )
Ranked among companies with meaningful Days Payable only.
ALKS' s Days Payable Range Over the Past 10 Years
Min: 21.49  Med: 30.39 Max: 67.67
Current: 27.44
21.49
67.67

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.40
ALKS's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. ALKS: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALKS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: -9.5 Max: 2.1
Current: -1.4
-16.1
2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 20.11
ALKS's Price-to-Net-Current-Asset-Value is ranked lower than
89% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. ALKS: 20.11 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALKS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.18  Med: 8.67 Max: 343
Current: 20.11
2.18
343
Price-to-Tangible-Book 6.14
ALKS's Price-to-Tangible-Book is ranked lower than
67% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. ALKS: 6.14 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALKS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.24  Med: 7.74 Max: 365.22
Current: 6.14
1.24
365.22
Price-to-Intrinsic-Value-Projected-FCF 7.61
ALKS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
82% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. ALKS: 7.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALKS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2  Med: 8.56 Max: 474
Current: 7.61
2
474
Price-to-Median-PS-Value 0.67
ALKS's Price-to-Median-PS-Value is ranked higher than
52% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. ALKS: 0.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALKS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.42 Max: 13.89
Current: 0.67
0.36
13.89
Earnings Yield (Greenblatt) % -2.00
ALKS's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. ALKS: -2.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALKS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -6  Med: -1.6 Max: 28.8
Current: -2
-6
28.8

More Statistics

Revenue (TTM) (Mil) $1,053.88
EPS (TTM) $ -0.89
Beta2.11
Volatility34.83%
52-Week Range $27.54 - 71.22
Shares Outstanding (Mil)155.38

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 1,041 1,056 1,038
EBIT (Mil $) 68 107 6
EBITDA (Mil $) 68 107 6
EPS ($) -1.19 -0.70 -1.68
EPS without NRI ($) -1.19 -0.70 -1.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}